AstraZeneca grants BioKangtai China rights to its COVID-19 vaccine, with a goal for annual production capacity of 200 million doses. Pfizer and BioNTech will provide 120 million doses of their …
( read original story …)
The Japan News
AstraZeneca grants BioKangtai China rights to its COVID-19 vaccine, with a goal for annual production capacity of 200 million doses. Pfizer and BioNTech will provide 120 million doses of their …
( read original story …)